Patient Experiences — Individual Results Vary

Maria presented with a 15 cm stage 3 breast tumour. She was treated with IPTLD low-dose chemotherapy combined with IV Vitamin C, ozone therapy, and hyperthermia over a 12-week protocol. Follow-up imaging measured a reduction from the original 15 cm mass to 3.7 cm of scar tissue. Importantly, she was not hospitalised at any point during treatment and reported generally fewer side effects compared to conventional treatments. Maria continued working full-time throughout the course and described her quality of life as largely unaffected by the treatment process.

Peter was referred to Cancer SA after conventional treatment options had been exhausted for his tongue cancer. He commenced IPTLD low-dose chemotherapy combined with high-dose IV Vitamin C. After 8 treatments, progressive reduction in the tumour was documented on clinical examination. By the 11th treatment, further measurable reduction was observed. Peter reported manageable side effects throughout the protocol and was able to maintain his daily routine during the treatment period.

Anna presented with stage 4 metastatic breast cancer. She was treated with an integrated protocol of IPTLD low-dose chemotherapy, ozone therapy, and hyperthermia. After completing 10 treatments, a follow-up PET scan confirmed no trace of active cancer was detected. Anna reported feeling well throughout the treatment course, with energy levels maintained and no requirement for hospitalisation. Her quality of life during treatment was described as significantly better than she had expected.

Elsa was diagnosed with Chronic Lymphocytic Leukaemia (CLL) and presented with a white blood cell (WBC) count of 61.6. She chose IPTLD low-dose chemotherapy as an alternative to conventional chemotherapy. After 7 treatments, her WBC count was measured at 8.5, representing a substantial reduction. Elsa did not require hospitalisation or blood transfusions at any stage. She reported maintaining her normal activities and described the treatment as tolerable with minimal disruption to her daily life.

Willem presented with CLL and a significantly elevated white blood cell count of 127. He was treated with IPTLD low-dose chemotherapy over a course of 13 treatments. His WBC count was subsequently measured at 11.5, representing a marked improvement. Notably, Willem did not require any blood transfusions during his treatment course. He reported feeling well throughout, maintaining his normal routine, and described the side effects as considerably milder than he had anticipated from chemotherapy.

Susan was diagnosed with stage 4 ovarian cancer and presented with a CA-125 tumour marker level of 807. Circulating Tumour Cell (CTC) chemo sensitivity testing was used to identify the most effective chemotherapy agents for her specific cancer. She then received a personalised IPTLD protocol over 18 treatments. Her CA-125 marker was subsequently measured at 6.8, a dramatic reduction. Susan continued her daily activities throughout the treatment course and reported a quality of life she described as far better than expected.

James, a young university student, presented with a large testicular mass measuring 20 x 15 x 10 cm. He was treated with IPTLD low-dose chemotherapy over 8 treatments. Following the IPTLD course, the mass was surgically removed and histological examination found it to be non-cancerous. James was able to continue his university studies throughout the treatment period without interruption. He reported minimal side effects and maintained his normal student lifestyle during the course of treatment.